The burden and impact of severe and long-term sequelae of meningococcal disease

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 6, 2013, Pages 597-604

  Vyse, Andrew ^a   Anonychuk, Andrea ^b   Jäkel, Anne ^c   Wieffer, Heather ^c   Nadel, Simon ^d  

^a GSK   (Belgium)

^b ABBOTT LABORATORIES   (United States)

^c Heron Evidence Development Ltd   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

literature review; meningococcal disease; mortality; Neisseria meningitidis; quality of life; sequelae

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULTHOOD; AMPUTATION; BEHAVIOR DISORDER; CHILDHOOD; COGNITIVE DEFECT; COMPLICATION; DISEASE SEVERITY; EMBASE; FATALITY; HEARING IMPAIRMENT; HUMAN; LONG TERM SEQUELA; MEDICAL CARE; MEDLINE; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; NEUROLOGICAL COMPLICATION; PHYSICAL DISEASE; QUALITY OF LIFE; REVIEW; SKIN SCAR; VACCINATION;

ADULT; AMPUTATION; CHILD; CICATRIX; HEARING LOSS; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 84878843326     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.42     Document Type: Review

References (52)

1. Nadel S, Kroll JS. Diagnosis and management of meningococcal disease: the need for centralized care. FEMS Microbiol. Rev. 31(1), 71-83 (2007).
2. Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr. Infect. Dis. J. 30(1), 3-6 (2011).
3. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 10(5), 317-328 (2010).
4. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 7, 47 (2009).
5. Ladhani SN, Flood JS, Ramsay ME et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 30(24), 3710-3716 (2012).
6. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med. 344(18), 1378-1388 (2001).
7. Halperin SA, Bettinger JA, Greenwood B et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl. 2), B26-B36 (2012).
8. Trotter CL, McVernon J, Ramsay ME et al.; SAGE subgroup. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26(35), 4434-4445 (2008).
9. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63 (2009).
10. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10(12), 853-861 (2010).
11. Buysse CM, Oranje AP, Zuidema E et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch. Dis. Child. 94(5), 381-386 (2009).
12. Bettinger JA, Scheifele DW, Kellner JD et al.; Canadian Immunization Monitoring Program, Active (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 28(9), 2130-2136 (2010).
13. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180(6), 1894-1901 (1999).
14. Goldacre MJ, Maisonneuve JJ. Mortality from meningococcal disease by day of the week: English national linked database study. J. Public Health (Oxf.) doi:10.1093/ pubmed/fdt004 (2013) (Epub ahead of print).
15. Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum. Vaccin. Immunother. 9(1), 162-171 (2013).
16. Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50(2), 184-191 (2010).
17. Sáfadi MAP, González-Ayala S, Jäkel A, Wieffer H, Moreno C, Vyse A. The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape. Epidemiol. Infect. 141, 447-458 (2013).
18. von Gottberg A, du Plessis M, Cohen C et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin. Infect. Dis. 46(3), 377-386 (2008).
19. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group. Epidemiol. Infect. 122(1), 41-49 (1999).
20. Howitz M, Lambertsen L, Simonsen JB, Christensen JJ, Mølbak K. Morbidity, mortality and spatial distribution of meningococcal disease, 1974-2007. Epidemiol. Infect. 137(11), 1631-1640 (2009).
21. Thompson MJ, Ninis N, Perera R et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 367(9508), 397-403 (2006).
22. Inwald DP, Tasker RC, Peters MJ, Nadel S; Paediatric Intensive Care Society Study Group (PICS-SG). Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch. Dis. Child. 94(5), 348-353 (2009).
23. Ninis N, Phillips C, Bailey L et al. The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. BMJ 330(7506), 1475 (2005).
24. Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicaemia. Lancet 2(8549), 38 (1987).
25. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ 327(7415), 596-597 (2003).
26. Booy R, Habibi P, Nadel S et al.; Meningococcal Research Group. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch. Dis. Child. 85(5), 386-390 (2001).
27. Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch. Dis. Child. 85(5), 382-385 (2001).
28. Barquet N, Domingo P, Caylà JA et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch. Intern. Med. 159(19), 2329-2340 (1999).
29. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 123(3), e502-e509 (2009).
30. Viner RM, Booy R, Johnson H et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 11(9), 774-783 (2012).
31. Darton T, Guiver M, Naylor S et al. Severity of meningococcal disease associated with genomic bacterial load. Clin. Infect. Dis. 48(5), 587-594 (2009).
32. Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcal meningitis. Neurology 79(15), 1563-1569 (2012).
33. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin. Infect. Dis. 26(5), 1159-1164 (1998).
34. Schildkamp RL, Lodder MC, Bijlmer HA, Dankert J, Scholten RJ. Clinical manifestations and course of meningococcal disease in 562 patients. Scand. J. Infect. Dis. 28(1), 47-51 (1996).
35. Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol. Infect. 112(1), 115-124 (1994).
36. Buysse CM, Raat H, Hazelzet JA et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch. Pediatr. Adolesc. Med. 162(11), 1036-1041 (2008).
37. Kutz JW, Simon LM, Chennupati SK, Giannoni CM, Manolidis S. Clinical predictors for hearing loss in children with bacterial meningitis. Arch. Otolaryngol. Head Neck Surg. 132(9), 941-945 (2006).
38. Naess A, Halstensen A, Nyland H et al. Sequelae one year after meningococcal disease. Acta Neurol. Scand. 89(2), 139-142 (1994).
39. Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJ. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr. Crit. Care Med. 6(4), 477-479 (2005).
40. Bache CE, Torode IP. Orthopaedic sequelae of meningococcal septicemia. J. Pediatr. Orthop. 26(1), 135-139 (2006).
41. Fellick JM, Thomson AP, Sills J, Hart CA. Neurological soft signs in mainstream pupils. Arch. Dis. Child. 85(5), 371-374 (2001).
42. Koomen I, Grobbee DE, Jennekens-Schinkel A, Roord JJ, van Furth AM. Parental perception of educational, behavioural and general health problems in school-age survivors of bacterial meningitis. Acta Paediatr. 92(2), 177-185 (2003).
43. Koomen I, Raat H, Jennekens-Schinkel A, Grobbee DE, Roord JJ, van Furth M. Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis. Qual. Life Res. 14(6), 1563-1572 (2005).
44. Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Arch. Dis. Child. 83(2), 111-116 (2000).
45. Halket S, de Louvois J, Holt DE, Harvey D. Long term follow up after meningitis in infancy: behaviour of teenagers. Arch. Dis. Child. 88(5), 395-398 (2003).
46. Hoogman M, van de Beek D, Weisfelt M, de Gans J, Schmand B. Cognitive outcome in adults after bacterial meningitis. J. Neurol. Neurosurg. Psychiatr. 78(10), 1092-1096 (2007).
47. Garralda ME, Gledhill J, Nadel S, Neasham D, O'Connor M, Shears D. Longer-term psychiatric adjustment of children and parents after meningococcal disease. Pediatr. Crit. Care Med. 10(6), 675-680 (2009).
48. Judge D, Nadel S, Vergnaud S, Garralda ME. Psychiatric adjustment following meningococcal disease treated on a PICU. Intensive Care Med. 28(5), 648-650 (2002).
49. Haines C. Parents' experiences of living through their child's suffering from and surviving severe meningococcal disease. Nurs. Crit. Care 10(2), 78-89 (2005).
50. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 33(5), 737-739 (2001).
51. Ventegodt S, Thegler S, Andreasen T et al. Clinical holistic medicine: psychodynamic short-time therapy complemented with bodywork. A clinical follow-up study of 109 patients. ScientificWorldJournal 6, 2220-2238 (2006).
52. Gorringe AR, Pajón R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum. Vaccin. Immunother. 8(2), 174-183 (2012).